Winton Group’s ADMA Biologics ADMA Stock Holding History

Winton Group’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Sell	25,600 -118,784	-82%	-$1.08M	0.01%	1000
2026 Q1	$1.3M	Buy	144,384 +69,138	+92%	+$1.09M	0.05%	442
2025 Q4	$1.37M	Buy	75,246 +4,715	+7%	+$79.5K	0.05%	371
2025 Q3	$1.03M	Sell	70,531 -202,286	-74%	-$3.47M	0.04%	447
2025 Q2	$4.97M	Buy	272,817 +205,094	+303%	+$4.18M	0.25%	100
2025 Q1	$1.34M	Buy	67,723 +3,814	+6%	+$66K	0.08%	236
2024 Q4	$1.1M	Buy	63,909 +9,573	+18%	+$180K	0.07%	281
2024 Q3	$1.09M	Buy	+54,336	New	+$845K	0.08%	252
2019 Q4	–	Sell	-10,712	Closed	-$48K	–	1520
2019 Q3	$48K	Buy	+10,712	New	+$44.8K	﹤0.01%	1500

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Winton Group's ADMA Position: Q2 2026 in Review

Winton Group reduced its ADMA Biologics (ADMA) stake by 82% in Q2 2026, selling an estimated $1.08M and leaving 25,600 shares worth $214K. The position accounts for 0.01% of the portfolio, ranked #1000.

Winton Group first reported a position in ADMA in Q3 2019 and has held it in 9 quarters since. The position peaked at $4.97M in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Winton Group held 25,600 shares of ADMA Biologics worth $214K as of Q2 2026.
Winton Group sold 118,784 ADMA Biologics shares in Q2 2026, an estimated $1.08M.
ADMA Biologics made up 0.01% of Winton Group's portfolio in Q2 2026, its #1000 holding.
Winton Group first reported a position in ADMA Biologics in Q3 2019 and has held it in 9 quarters since.
Winton Group's ADMA Biologics position peaked at $4.97M in Q2 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.